-
Posted by
Two Blokes May 25 -
Filed in
Stock
-
2 views
In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective HER2-directed ADC, was $596 million in the first quarter of 2025, an increase of 29.3% year-over-year. Meanwhile, sales of Ultomiris, the flagship of AstraZeneca's Rare Disease segment and the successor of Soliris, reached $1.05 billion in the first three months of 2025, increasing by 22.2% year-on-year.
